Midatech Pharma Plc FCF yield
What is the FCF yield of Midatech Pharma Plc?
The FCF yield of Midatech Pharma Plc is -556.88%
What is the definition of FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield of companies in the Health Care sector on LSE compared to Midatech Pharma Plc
What does Midatech Pharma Plc do?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Companies with fcf yield similar to Midatech Pharma Plc
- Catasys has FCF yield of -564.63%
- Exicure has FCF yield of -560.79%
- Exicure has FCF yield of -560.79%
- Exicure has FCF yield of -560.79%
- Exicure has FCF yield of -560.79%
- Exicure has FCF yield of -560.79%
- Midatech Pharma Plc has FCF yield of -556.88%
- Anconia Resources has FCF yield of -554.97%
- Exicure has FCF yield of -552.63%
- BiomX Inc has FCF yield of -552.51%
- Berkwood Resources has FCF yield of -550.81%
- Unico American has FCF yield of -547.20%
- Alteryx has FCF yield of -544.68%